Literature DB >> 21093206

Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller.

H W Lai1, S J Kuo, L S Chen, C W Chi, S T Chen, T W Chang, D R Chen.   

Abstract

AIMS: The purpose of this study was to clarify the prognostic significance of triple-negative breast cancer (TNBC) with a tumor size ≤ 1 cm.
MATERIALS AND METHODS: Patients with primary operable breast cancer with a tumor size ≤ 1 cm were enrolled at Changhua Christian Hospital and National Cheng-Kung University Hospital. Tumors negative for ER, PR, and HER-2 were classified as TNBCs and compared with tumors with any receptor positivity (non-TNBC) for disease-free survival (DFS) and cancer-specific survival (CSS).
RESULTS: From 1995 to 2006, a total of 377 patients with tumor size ≤ 1 cm were enrolled. Compared with non-TNBC patients, TNBC patients with a tumor size ≤ 1 cm as a whole or in a lymph node-positive subgroup were not associated with a poorer 5-year DFS and CSS. In lymph node-negative patients (pT1a-bN0M0), TNBC was associated with a poorer 5-year CSS but not DFS. Compared with the hormone receptor-positive, HER-2-negative subgroup, TNBC was associated with poorer DFS and CSS. In the multivariate Cox regression hazard analysis, lymph node invasion was the most important cause of disease recurrence and cancer-specific death.
CONCLUSION: TNBC is very likely an independent risk factor in small (≤1 cm) node-negative invasive breast cancer. With tumors 1 cm and smaller, lymph node invasion was the single most important prognostic factor.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21093206     DOI: 10.1016/j.ejso.2010.10.003

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  Three-Dimensional Breast Cancer Models Mimic Hallmarks of Size-Induced Tumor Progression.

Authors:  Manjulata Singh; Shilpaa Mukundan; Maria Jaramillo; Steffi Oesterreich; Shilpa Sant
Journal:  Cancer Res       Date:  2016-05-23       Impact factor: 12.701

2.  Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis.

Authors:  T Gamucci; A Vaccaro; F Ciancola; L Pizzuti; I Sperduti; L Moscetti; F Longo; M A Fabbri; M A Giampaolo; L Mentuccia; L Di Lauro; P Vici
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-15       Impact factor: 4.553

3.  Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer.

Authors:  Shanshan Wang; Xuan Zou; Yajie Chen; William C Cho; Xiang Zhou
Journal:  Front Genet       Date:  2021-01-28       Impact factor: 4.599

4.  lncRNA LINC01315 promotes malignancy of triple-negative breast cancer and predicts poor outcomes by modulating microRNA-876-5p/GRK5.

Authors:  Yan Xiu; Shannan Cao; Ru Jiang; Yuming Zhou
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

5.  Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy.

Authors:  Young Jae Ryu; Shin Jae Kang; Jin Seong Cho; Jung Han Yoon; Min Ho Park
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

6.  Clinical features and their effect on outcomes of patients with triple negative breast cancer with or without lymph node involvement.

Authors:  Monika Sobočan; Maja Turk; Pija Čater; Nina Čas Sikošek; Bojana Crnobrnja; Iztok Takač; Darja Arko
Journal:  J Int Med Res       Date:  2019-12-11       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.